Arrowhead Pharmaceuticals, Inc. (ARWR) shareholders
Close on Nov 17, 2026Market cap $6.07BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 14,232,545 | 10.10% | 13G (passive) amendment | Jun 30, 2026 |
| Avoro Capital Advisors LLC Joint filing with Behzad Aghazadeh (9.64%) | 13,823,383 | 9.64% | 13G (passive) amendment | Jun 30, 2026 |
| Sarepta Therapeutics, Inc. Joint filing with Sarepta Therapeutics Investments, Inc. (9.50%) | 11,926,301 | 9.50% | 13D (active) | Feb 7, 2025 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (8.30%) | 11,517,441 | 8.30% | 13G (passive) amendment | Jun 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (6.60%) | 9,307,350 | 6.60% | 13G (passive) amendment | Sep 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (5.20%) | 7,349,107 | 5.20% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 7,081,293 | 5.05% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARWR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14,830,553 | 10.50% | $1.21B | −3,330,966 | 0.02% |
| Avoro Capital Advisors LLC | 11,355,555 | 8.04% | $925.59M | +655,556 | 8.31% |
| FMR LLC | 8,039,804 | 5.69% | $655.32M | +773,152 | 0.03% |
| Vanguard Portfolio Management LLC | 6,351,355 | 4.50% | $517.70M | −794,781 | 0.02% |
| Vanguard Capital Management LLC | 6,110,953 | 4.33% | $498.10M | +78,537 | 0.01% |
| State Street Corp | 5,694,640 | 4.03% | $464.17M | −801,490 | 0.01% |
| Norges Bank | 3,896,536 | 2.76% | $317.61M | New | 0.03% |
| Invesco Ltd. | 3,883,976 | 2.75% | $316.58M | +603,329 | 0.03% |
| Geode Capital Management, LLC | 3,530,612 | 2.50% | $298.81M | −748,216 | 0.02% |
| Fred Alger Management, LLC | 3,301,919 | 2.34% | $269.14M | −40,574 | 0.90% |
| Baker Bros. Advisors LP | 1,992,783 | 1.41% | $162.43M | – | 0.81% |
| Siren, L.L.C. | 1,715,476 | 1.21% | $139.83M | +100,000 | 2.83% |
| Vestal Point Capital, LP | 1,575,000 | 1.12% | $128.38M | −700,000 | 3.00% |
| Deerfield Management Company, L.P. (Series C) | 1,389,055 | 0.98% | $113.22M | −184,242 | 1.18% |
| First Trust Advisors LP | 1,352,918 | 0.96% | $110.28M | +1,203,770 | 0.06% |
| Driehaus Capital Management LLC | 1,350,556 | 0.96% | $110.08M | +160,221 | 0.64% |
| Jupiter Topco LLC | 1,221,596 | 0.86% | $99.62M | New | 0.04% |
| Northern Trust Corp | 1,192,868 | 0.84% | $97.23M | −462,969 | 0.01% |
| Dimensional Fund Advisors LP | 1,181,608 | 0.84% | $96.31M | +573,077 | 0.02% |
| Goldman Sachs Group Inc | 1,150,007 | 0.81% | $93.74M | −589,916 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 499 | 120M | 84.6% | 126 / 153 | 157 / 58 | 18M | 18M |
| Q1 2026 | 437 | 121M | 85.5% | 106 / 171 | 112 / 62 | 36M | 16M |
| Q4 2025 | 401 | 116M | 82.1% | 127 / 125 | 110 / 27 | 17M | 13M |
| Q3 2025 | 303 | 112M | 79.1% | 66 / 101 | 82 / 41 | 17M | 11M |
| Q2 2025 | 281 | 106M | 75.2% | 57 / 97 | 82 / 38 | 13M | 12M |
| Q1 2025 | 264 | 105M | 74.5% | 43 / 89 | 81 / 47 | 17M | 11M |
| Q4 2024 | 270 | 100M | 70.6% | 44 / 93 | 85 / 42 | 9M | 10M |
| Q3 2024 | 272 | 100M | 70.8% | 34 / 92 | 90 / 32 | 26M | 11M |
| Q2 2024 | 272 | 100M | 70.8% | 34 / 97 | 87 / 34 | 9M | 9M |
| Q1 2024 | 273 | 102M | 72.0% | 40 / 107 | 75 / 30 | 29M | 9M |
| Q4 2023 | 266 | 81M | 57.5% | 44 / 77 | 96 / 34 | 13M | 7M |
| Q3 2023 | 256 | 75M | 53.0% | 21 / 91 | 96 / 38 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
469 funds held ARWR in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ARWR | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 4,820,474 | 3.41% | $392.92M | 0.32% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,246,637 | 3.01% | $346.14M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,067,819 | 2.17% | $250.06M | 0.13% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,362,371 | 1.67% | $184.05M | 0.19% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,768,635 | 1.25% | $144.16M | 0.31% | Jun 30, 2026 |
| Invesco S&P MidCap Momentum ETF | 1,736,475 | 1.23% | $146.99M | 2.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,614,924 | 1.14% | $131.63M | 0.13% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,407,587 | 1.00% | $114.73M | 1.07% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 1,165,127 | 0.82% | $94.97M | 3.38% | Jun 30, 2026 |
| iShares Biotechnology ETF | 937,699 | 0.66% | $76.43M | 0.84% | Jun 30, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 842,687 | 0.60% | $68.69M | 0.61% | Jun 30, 2026 |
| Alger Focus Equity Fund | 762,514 | 0.54% | $64.55M | 0.91% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 720,889 | 0.51% | $56.16M | 0.13% | May 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF | 712,985 | 0.50% | $58.12M | 0.32% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 694,990 | 0.49% | $54.15M | 0.31% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer, Director | 3,798,510 | 2.69% | Jan 5, 2026 |
| Daniel Joseph Apel | Chief Financial Officer | 172,792 | 0.12% | Apr 24, 2026 |
| James C. Hamilton | Chief Medical Officer | 226,958 | 0.16% | Apr 24, 2026 |
| Patrick O'Brien | COO | 472,848 | 0.33% | Jan 8, 2026 |
| Kenneth Allen Myszkowski | Chief Financial Officer | 465,433 | 0.33% | Jan 7, 2025 |
| Adeoye Y. Olukotun | Director | 31,600 | 0.02% | Aug 20, 2026 |
| Michael S. Perry | Director | 111,459 | 0.08% | Aug 20, 2026 |
| Matthew Gregory Cohen | Director | 11,882 | 0.01% | Jun 17, 2026 |
| Hongbo Lu | Director | 57,662 | 0.04% | May 14, 2026 |
| Mauro Ferrari | Director | 69,053 | 0.05% | Dec 30, 2025 |
| William D. Waddill | Director | 56,563 | 0.04% | Dec 23, 2025 |
| Victoria Vakiener | Director | 37,683 | 0.03% | Dec 23, 2025 |
| Douglas S. Ingram | Director | 46,215 | 0.03% | Dec 18, 2025 |
| Douglas B. Given | Director | 136,667 | 0.10% | Dec 18, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael S. Perry Director | Aug 18, 2026 | Sale | −11,600 | $87.30 | $1.01M | 111,459 |
| Adeoye Y. Olukotun Director | Aug 18, 2026 | Sale | −2,000 | $86.96 | $173.92K | 31,600 |
| Matthew Gregory Cohen Director | Jun 15, 2026 | Award | +11,882 | – | – | 11,882 |
| Hongbo Lu Director | May 12, 2026 | Sale(10b5-1 plan) | −2,970 | $76.88 | $228.33K | 52,012 |
| James C. Hamilton Chief Medical Officer | Apr 23, 2026 | Sale(10b5-1 plan) | −10,000 | $75.00 | $750.00K | 226,958 |
| Daniel Joseph Apel Chief Financial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −3,208 | $70.11 | $224.91K | 172,792 |
| Daniel Joseph Apel Chief Financial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −1,157 | $70.45 | $81.51K | 171,635 |
| Daniel Joseph Apel Chief Financial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −8,730 | $71.92 | $627.86K | 162,905 |
| James C. Hamilton Chief Medical Officer | Mar 5, 2026 | Sale(10b5-1 plan) | −10,000 | $64.19 | $641.90K | 236,958 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −440 | – | – | 472,848 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −540 | – | – | 474,368 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −540 | – | – | 473,828 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −440 | – | – | 472,408 |
| Patrick O'Brien COO | Jan 6, 2026 | Award | +75,000 | – | – | 547,408 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −540 | – | – | 473,288 |
| Daniel Joseph Apel Chief Financial Officer | Jan 6, 2026 | Award | +75,000 | – | – | 176,200 |
| James C. Hamilton Chief Medical Officer | Jan 6, 2026 | Award | +75,000 | – | – | 246,958 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −12,711 | $63.95 | $812.87K | 173,904 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −437 | $65.97 | $28.83K | 172,267 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −1,200 | $64.49 | $77.39K | 172,704 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −309 | $68.00 | $21.01K | 171,958 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −14,792 | $63.01 | $932.04K | 186,615 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −6,090 | $62.28 | $379.29K | 201,407 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −4,625 | $61.24 | $283.24K | 207,497 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −2,336 | $64.04 | $149.60K | 474,954 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −5,873 | $62.91 | $369.47K | 477,290 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −900 | $62.25 | $56.03K | 483,163 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −600 | $61.12 | $36.67K | 484,063 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −313 | $68.00 | $21.28K | 484,663 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −900 | $66.01 | $59.41K | 484,976 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −2,700 | $64.44 | $173.99K | 485,876 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −11,842 | $63.84 | $755.99K | 488,576 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −13,451 | $62.96 | $846.87K | 500,418 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −6,164 | $62.23 | $383.59K | 513,869 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −4,368 | $61.20 | $267.32K | 520,033 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −46 | $68.00 | $3.13K | 474,908 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −7,416 | $65.88 | $488.57K | 3,798,510 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −5,771 | $66.39 | $383.14K | 3,792,739 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 526,081 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 524,401 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 524,961 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 525,521 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 526,641 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 29, 2025 | Option exercise | +35,181 | $6.15 | $216.36K | 3,841,107 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 29, 2025 | Option exercise | +16,545 | $6.15 | $101.75K | 3,857,652 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 29, 2025 | Sale(10b5-1 plan) | −35,181 | $69.33 | $2.44M | 3,822,471 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 29, 2025 | Sale(10b5-1 plan) | −16,545 | $68.69 | $1.14M | 3,805,926 |
| Mauro Ferrari Director | Dec 26, 2025 | Sale(10b5-1 plan) | −7,530 | $70.00 | $527.10K | 69,053 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 22, 2025 | Sale(10b5-1 plan) | −10,012 | $68.33 | $684.12K | 3,808,500 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 22, 2025 | Sale(10b5-1 plan) | −2,574 | $68.85 | $177.22K | 3,805,926 |
| Adeoye Y. Olukotun Director | Dec 19, 2025 | Sale(10b5-1 plan) | −827 | $68.48 | $56.63K | 33,600 |
| Adeoye Y. Olukotun Director | Dec 19, 2025 | Sale(10b5-1 plan) | −6,083 | $68.04 | $413.89K | 34,427 |
| Adeoye Y. Olukotun Director | Dec 19, 2025 | Sale(10b5-1 plan) | −3,090 | $66.70 | $206.10K | 40,510 |
| William D. Waddill Director | Dec 19, 2025 | Sale(10b5-1 plan) | −500 | $68.53 | $34.27K | 56,563 |
| William D. Waddill Director | Dec 19, 2025 | Sale(10b5-1 plan) | −2,416 | $66.66 | $161.05K | 62,514 |
| William D. Waddill Director | Dec 19, 2025 | Sale(10b5-1 plan) | −5,451 | $68.01 | $370.72K | 57,063 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 19, 2025 | Sale(10b5-1 plan) | −1,319 | $68.48 | $90.33K | 3,818,512 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 19, 2025 | Sale(10b5-1 plan) | −8,147 | $68.01 | $554.08K | 3,819,831 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 19, 2025 | Sale(10b5-1 plan) | −3,979 | $66.67 | $265.28K | 3,827,978 |
| Victoria Vakiener Director | Dec 19, 2025 | Sale(10b5-1 plan) | −5,281 | $67.97 | $358.95K | 37,683 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arrowhead Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,174 shares on Sep 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael S. Perry Director | Aug 18, 2026 | 11,600 | $1.01M | Aug 18, 2026 | Compensation |
| Adeoye Y. Olukotun Director | Aug 18, 2026 | 2,000 | $173.88K | Aug 18, 2026 | Compensation |
| Daniel Joseph Apel Officer | May 19, 2026 | 13,095 | $934.21K | Apr 22, 2026 | Bonus |
| Hongbo Lu Officer | May 19, 2026 | 2,970 | $228.30K | May 12, 2026 | Compensation |
| James C. Hamilton Officer | May 19, 2026 | 10,000 | $750.00K | Apr 23, 2026 | Compensation |
| Hongbo Lu Officer | May 12, 2026 | 2,970 | $228.30K | May 12, 2026 | Compensation |
| James C. Hamilton Officer | Apr 23, 2026 | 10,000 | $750.00K | Apr 23, 2026 | Compensation |
| Daniel Joseph Apel Officer | Apr 22, 2026 | 13,095 | $934.21K | Apr 22, 2026 | Bonus |
| James C. Hamilton Officer | Mar 5, 2026 | 10,000 | $641.87K | Mar 5, 2026 | Compensation |
| Patrick O'Brien Officer | Jan 5, 2026 | 49,493 | $3.12M | Jan 5, 2026 | Compensation |
| James C. Hamilton Officer | Jan 5, 2026 | 39,728 | $2.51M | Jan 5, 2026 | Compensation |
| James C. Hamilton Officer | Jan 5, 2026 | 40,164 | $2.53M | Jan 5, 2026 | Compensation |
| Christopher Richard Anzalone Officer | Jan 2, 2026 | 13,187 | $871.67K | Jan 2, 2026 | Compensation |
| Christopher Richard Anzalone Officer | Dec 29, 2025 | 51,726 | $3.58M | Dec 29, 2025 | Compensation |
| Mauro Ferrari Director | Dec 29, 2025 | 7,530 | $527.07K | Dec 26, 2025 | Compensation |
Congress trades
1 trade in Arrowhead Pharmaceuticals reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Daniel Goldman NY10 | Sold | Jan 31, 2023 | $1K–15K | Feb 24, 2023 |
See a number that looks wrong?